Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia.

MLA

Krogh-Madsen, Mikkel, et al. “Population Pharmacokinetics of Cytarabine, Etoposide, and Daunorubicin in the Treatment for Acute Myeloid Leukemia.” Cancer Chemotherapy and Pharmacology, vol. 69, no. 5, May 2012, pp. 1155–63. EBSCOhost, https://doi.org/10.1007/s00280-011-1800-z.

APA

Krogh-Madsen, M., Bender, B., Jensen, M. K., Nielsen, O. J., Friberg, L. E., & Honoré, P. H. (2012). Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 69(5), 1155–1163. https://doi.org/10.1007/s00280-011-1800-z

Chicago

Krogh-Madsen, Mikkel, Brendan Bender, Morten Krogh Jensen, Ove Juul Nielsen, Lena E Friberg, and Per Hartvig Honoré. 2012. “Population Pharmacokinetics of Cytarabine, Etoposide, and Daunorubicin in the Treatment for Acute Myeloid Leukemia.” Cancer Chemotherapy and Pharmacology 69 (5): 1155–63. doi:10.1007/s00280-011-1800-z.